The potential utility of smell testing to screen for neurodegenerative disorders. (1st February 2022)

• Record Type: Journal Article
• Authors: Goodwin, Gregory R.; Bestwick, Jonathan P.; Noyce, Alastair J.
• Is Part Of: Expert review of molecular diagnostics. Volume 22:Number 2(2022)
• Page Start: 139
• Page End: 148
• Publication Date: 2022-02-01
• Subjects: Screening -- neurodegeneration -- smell -- Alzheimer's disease -- Parkinson's disease; Molecular diagnosis -- Periodicals; 616.0758205
• DOI: 10.1080/14737159.2022.2037424
• Languages: English
• ISSNs: 1473-7159

Abstract

ABSTRACT: Introduction: Loss of smell is a common early feature of neurodegenerative diseases including Alzheimer's and Parkinson's disease. Identifying these conditions in their early stages is important to understand more about early pathophysiological events and the development of disease modifying therapies. Smell testing may be an effective future tool for screening large populations for early neurodegeneration. Areas Covered: In this review, we appraise the evidence for, and discuss the likelihood of, the use of smell testing in large screening programs to detect early neurodegeneration. We evaluate the predictive power of smell tests for neurodegenerative disease, compare performance to other established screening programs, and discuss ethical and practical considerations and limitations. Expert Opinion: Even if disease modifying therapies were available for neurodegenerative disease, smell tests alone are unlikely to have high enough predictive power to be used in a future screening program. However, we believe they could be a valuable component of a short battery of tests or part of a stepwise process that together could more accurately identify early neurodegeneration in large populations.